[An experimental study on repairing bone defect with composite of beta-tricalcium phosphate-hyaluronic acid-type I collagen-marrow stromal cells].
OBJECTIVE
To observe the ability to repair bilateral radius bone defect with the composite of beta-tricalcium phosphate (PTCP), hyaluronic acid (HA), type I collagen (COL-I) and induced marrow stromal cells (MSCs), and to investigate the feasibility of the composite as a bone substitute material.


METHODS
The MSCs of the New Zealand white rabbits were induced into osteoblasts, then combined with beta-TCP, HA and COL-I. Thirty New Zealand white rabbits were made the bilateral radius bone defects of 2 cm and divided into groups A, B and C. After 8 weeks, beta-TCP-HA-COL-I-MSCs (group A, n=27 sides), autograft (group B, n=27 sides)and no implant (group C as control, n=6 sides) were implanted into the areas of bilateral radius bone defects, respectively. The structure of the composite was observed by scanning electron microscope. The repairing effect was observed by gross, histomorphology, X-ray examination, and the degradation rate of inorganic substance at 4, 8 and 12 weeks. The osteogenic area and biomechanics of group A were compared with those of group B at 12 weeks.


RESULTS
The MSCs could stably grow in vitro, relatively rapidly proliferated, and could be induced into the osteoblasts. The composite was porous. The results of gross, histomorphology and X-ray showed that the bone defects were perfectly repaired in group A and group B, but not in group C. The osteogenic area or biomechanics had no statistically significant difference between groups A and B (P> 0.05). The weight of inorganic substance in group A were 75%, 57% and 42% at 4, 8, 12 weeks, respectively.


CONCLUSIONS
MSCs can be used as seed cells in the bone tissue engineering. The composite has porous structure, no reactions of toxicity to the tissue and rapid degradation, and it is an ideal carrier of seed cells. The beta-TCP-HA-COL-I-MSCs composite has the high ability of repairing bone defect and can serve as an autograft substitute material.
Wei
Ailin
A
Department of Orthopaedics, People's Hospital of Wuhan University, Wuhan Hubei, 430060, P. R. China.
Liu
Shiqing
S
Peng
Hao
H
Tao
Haiying
H
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry*; D001854:Bone Marrow Cells / Q000166:cytology*; D018786:Bone Substitutes; D016025:Bone Transplantation / Q000379:methods; D002130:Calcium Phosphates / Q000737:chemistry; D002478:Cells, Cultured; D024042:Collagen Type I / Q000737:chemistry; D004195:Disease Models, Animal; D005260:Female; D006820:Hyaluronic Acid / Q000737:chemistry; D008297:Male; D011817:Rabbits; D011884:Radius / Q000293:injuries / Q000601:surgery; D011897:Random Allocation; D017154:Stromal Cells / Q000166:cytology*; D023822:Tissue Engineering / Q000379:methods; D054457:Tissue Scaffolds / Q000737:chemistry*; D014182:Transplantation, Autologous
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; D024042:Collagen Type I; C485817:beta-tricalcium phosphate; D006820:Hyaluronic Acid